Unjoni Ewropea - Malti - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - bretaris genuair huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide, formoterol fumarate dihydrate - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - duaklir genuair huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - eklira genuair huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - brimica genuair huwa indikat bħala l-manutenzjoni bronkodilatur trattament għall-arja ostruzzjoni u l-serħan mis-sintomi fil-pazjenti adulti bil-marda pulmonari ostruttiva kronika (copd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp dohme limited - lamivudine, raltegravir potassju - infezzjonijiet ta 'hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebis huwa indikat f ' għaqda ma ' oħrajn anti‑retroviral prodotti mediċinali għat-trattament ta ' l-infezzjoni tal-virus ta ' immunodefiċjenza umani (hiv‑1) fl-adulti, adolixxenti u tfal mill-età ta ' 6 snin u mill-anqas 30 kg mingħajr preżent użin jew imgħoddi evidenza ta ' reżistenza virali għal aġenti antivirali tal-insti (integrase il-faxxa trasferiment inhibitor) u nrti (inibitur ta ' rivers transcriptase nukleosidi) klassijiet (ara sezzjonijiet 4. 2, 4. 4 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaċċini - hexyon (dtap-ipv-hb-hib) huwa indikat għat-tilqim primarja u booster tat-trabi u toddlers minn sitt ġimgħat ta ' età kontra diphtheria, tetanus, pertussis, epatite b, poliomyelitis u invażivi mard ikkawżat minn influwenza Ħemofillika tip b (hib). l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - marda ta 'parkinson - mediċini kontra l-parkinson - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - infezzjonijiet pnewmokokkali - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. ara t-taqsimiet 4. 4 u 5. 1 għal informazzjoni dwar il-protezzjoni kontra serotipi pnewmokokkiċi speċifiċi. the use of vaxneuvance should be in accordance with official recommendations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - epatite b, antiġen tal-wiċċ rikombinanti - hepatitis b; immunization - vaċċini - 5 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-b virus. l-speċifiċi fil-kategoriji tar-riskju biex jiġu immunizzati għandhom jiġu determinati fuq il-bażi tar-rakkomandazzjonijiet uffiċjali. huwa mistenni li epatite d tiġi evitata wkoll permezz tat-tilqima b'hbvaxpro billi l-epatite d (ikkawżata mill-aġent delta) ma tfeġġx fl-assenza ta ' l-epatite b infezzjoni. 10 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-b virus. l-speċifiċi fil-kategoriji tar-riskju biex jiġu immunizzati għandhom jiġu determinati fuq il-bażi tar-rakkomandazzjonijiet uffiċjali. huwa mistenni li epatite d tiġi evitata wkoll permezz tat-tilqima b'hbvaxpro billi l-epatite d (ikkawżata mill-aġent delta) ma tfeġġx fl-assenza ta ' l-epatite b infezzjoni. 40 micrograms hbvaxpro is indicated for the active immunisation against hepatitis-b-virus infection caused by all known subtypes in predialysis and dialysis adult patients. huwa mistenni li epatite d tiġi evitata wkoll permezz tat-tilqima b'hbvaxpro billi l-epatite d (ikkawżata mill-aġent delta) ma sseħħx fin-nuqqas ta ' infezzjoni tal-epatite b.